Innate defences against methicillin-resistant Staphylococcus aureus (MRSA) infection

Journal of Pathology

Volumn 208, Issue 2, 2006, Pages 249-260

  Komatsuzawa, Hitoshi ^a   Ouhara, Kazuhisa ^a   Yamada, Sakuo ^b   Fujiwara, Tamaki ^a   Sayama, Koji ^c   Hashimoto, Koji ^c   Sugai, Motoyuki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cathelicidin; Defensin; Immunity; Innate; Keratinocytes; MRSA; Staphylococcus aureus

Indexed keywords

ANTIBODY; BETA DEFENSIN 2; BETA DEFENSIN 3; CATHELICIDIN; POLYPEPTIDE ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; HOST CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS INFECTION;

ALPHA-DEFENSINS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BETA-DEFENSINS; HUMANS; IMMUNITY, NATURAL; METHICILLIN RESISTANCE; MODELS, IMMUNOLOGICAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 31144468526     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.1898     Document Type: Review

References (128)

1. Fellermann K, Wehkamp J, Herrlinger KR, Stange EF. Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol 2003;15:627-634.
2. Wehkamp J, Fellermann K, Herrlinger KR, Baxmann S, Schmidt K, Schwind B, et al. Human beta-defensin 2 but not beta-defensin-1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002;14:745-752.
3. Fellermann K, Wehkamp J, Stange EF. Antimicrobial peptides in the skin. N Engl J Med 2003;348:361-363.
4. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-1160.
5. Putsep K, Carlsson G, Boman HG, Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 2002;360:1144-1149.
6. van Wetering S, Sterk PJ, Rabe KF, Hiemstra PS. Defensins: key players or bystanders in infection, injury, and repair in the lung? J Allergy Clin Immunol 1999;104:1131-1138.
7. Devine DA. Antimicrobial peptides in defence of the oral and respiratory tracts. Mol Immunol 2003;40:431-443.
8. Harder J, Bartels J, Christophers E, Schröder JM. A peptide antibiotic from human skin. Nature 1997;387:861.
9. Harder J, Schröder JM. Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. J Leukoc Biol 2005;77:476-486.
10. Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001;414:454-457.
11. Morrison G, Kilanowski F, Davidson D, Dorin J. Characterization of the mouse beta defensin 1, Defb1, mutant mouse model. Infect Immun 2002;70:3053-3060.
12. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339:520-532.
13. Manders SM. Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol 1998;39:383-398.
14. Balaban N, Rasooly A. Staphylococcal enterotoxins. Int J Food Microbiol 2000;61:1-10.
15. Foster TJ. The Staphylococcus aureus 'superbug'. J Clin Invest 2004;114:1693-1696.
16. Peterson PK, Wilkinson BJ, Kim Y, Schmeling D, Quie PG. Influence of encapsulation on staphylococcal opsonization and phagocytosis by human polymorphonuclear leukocytes. Infect Immun 1978;19:943-949.
17. Xu S, Arbeit RD, Lee JC. Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun 1992;60:1358-1362.
18. Cunnion KM, Zhang HM, Frank MM. Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis. Infect Immun 2003;71:656-662.
19. O'Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 2004;17:218-234.
20. Maple PA, Hamilton-Miller JM, Brumfitt W. World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus. Lancet 1989;11:537-540.
21. Martin MA. Methicillin-resistant Staphylococcus aureus: the persistent resistant nosocomial pathogen. Curr Clin Top Infect Dis 1994;14:170-191.
22. Kirby WMM. Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. Science 1944;99: 452-453.
23. Thornsberry C. The development of antimicrobial resistance in staphylococci. J Antimicrob Chemother 1988;21(Suppl C):9-17.
24. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7:178-182.
25. de Lencastre H, de Jonge BL, Matthews PR, Tomasz A. Molecular aspects of methicillin resistance in Staphylococcus aureus. J Antimicrob Chemother 1994;33:7-24.
26. Berger-Bächi B. Resistance mechanisms of Gram-positive bacteria. Int J Med Microbiol 2002;292:27-35.
27. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340:517-523.
28. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.
29. Bobin-Dubreux S, Reverdy ME, Nervi C, Rougier M, Bolmstrom A, Vandenesch F, et al. Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative. Antimicrob Agents Chemother 2001;45:349-352.
30. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001;1:147-155.
31. Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004;39:539-545.
32. Goldrick B. First reported case of VRSA in the United States. Am J Nurs 2002;102:17.
33. Whitener CJ, Park SY, Browne FA, Parent LJ, Julian K, Bozdogan B, et al. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis 2004;38:1049-1055.
34. Clark NC, Weigel LM, Patel JB, Tenover FC. Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania. Antimicrob Agents Chemother 2005;49:470-472.
35. Ma XX, Ito T, Tiensasitorn C, Jamklang M, Chongtrakool P, Boyle-Varvra S, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001;46:1147-1152.
36. Hiramatsu K, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 2001;9:486-493.
37. Hiramatsu K, Katayama Y, Yuzawa H, Ito T. Molecular genetics of methicillin-resistant Staphylococcus aureus. Int J Med Microbiol 2002;292:67-74.
38. Robinson DA, Enright MC. Multilocus sequence typing and the evolution of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2004;10:92-97.
39. Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 1985;76:1427-1435.
40. Ganz T, Lehrer RI. Defensins. Pharmacol Ther 1995;66: 191-205.
41. Lehrer RI, Ganz T. Antimicrobial peptides in mammalian and insect host defense. Curr Opin Immunol 1999;11:23-27.
42. Nguyen TX, Cole AM, Lehrer RI. Evolution of primate theta-defensins: a serpentine path to a sweet tooth. Peptides 2003;24:1647-1654.
43. Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nature Immunol 2005;6:551-557.
44. Cole AM, Hong T, Boo LM, Nguyen T, Zhao C, Bristol G, et al. Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-I. Proc Natl Acad Sci U S A 2002;99:1813-1818.
45. Yang D, Biragyn A, Kwak LW, Oppenheim JJ. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol 2002;23:291-296.
46. Jones DE, Bevins CL. Defensin-6 mRNA in human Paneth cells: implications for antimicrobial peptides in host defense of the human bowel. FEBS Lett 1993;315:187-192.
47. Raj PA, Dentino AR. Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiol Lett 2002;206:9-18.
48. Cunliffe RN. Alpha-defensins in the gastrointestinal tract. Mol Immunol 2003;40:463-467.
49. Daher KA, Selsted ME, Lehrer RI. Direct inactivation of viruses by human granulocyte defensins. J Virol 1986;60:1068-1074.
50. Scott MG, Hancock REW. Cationic antimicrobial peptides and their multifunctional role in the immune system. Crit Rev Immunol 2002;20:407-431.
51. Zhang L, Yu W, He T, Yu J, Caffrey RE, Dalmasso EA, et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 2002;298:995-1000.
52. Cole AM, Lehrer RI. Minidefensins: antimicrobial peptides with activity against HIV-1. Curr Pharm Des 2003;9:1463-1473.
53. Welling MM, Hiemstra PS, van Den Barselaar MT, Paulusma-Annema A, Nibbering PH, Pauwels EK, et al. Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation. J Clin Invest 1998;102:1583-1590.
54. Sharma S, Verma I, Khuller GK. Therapeutic potential of human neutrophil peptide I against experimental tuberculosis. Antimicrob Agents Chemother 2001;45:639-640.
55. Kalita A, Verma I, Khuller GK. Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. J Infect Dis 2004;190:1476-1480.
56. Territo MC, Ganz T, Selsted ME, Lehrer RI. Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest 1989;84:2017-2020.
57. Verbanac D, Zanetti M, Romeo D. Chemotactic and protease-inhibiting activities of antibiotic peptide precursors. FEBS Lett 1993;371:255-258.
58. Huang HJ, Ross CR, Blecha F. Chemoattractant properties of PR-39, a neutrophil antibacterial peptide. J Leukoc Biol 1997;61:624-629.
59. Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract native T and immature dendritic cells. J Leukoc Biol 2000;68:9-14.
60. Krisanaprakornkit S, Weinberg A, Perezz CN, Dale BA. Expression of the peptide antibiotic human β-defensin 1 in cultured gingival epithelial cells and gingival tissue. Infect Immun 1998;66:4222-4228.
61. Valore EV, Park CH, Quayle AJ, Wiles KR, McCray PB Jr, Ganz T. Human β-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest 1998;101:1633-1642.
62. Mathews M, Jia HP, Guthmiller IM, Losh G, Graham S, Johnson GK, et al. Production of β-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun 1999;67:2740-2745.
63. Schröder JM, Harder J. Human beta-defensin-2. Int J Biochem Cell Biol 1999;31:645-651.
64. Bals R. Epithelial antimicrobial peptides in host defense against infection. Respir Res 2000;1:141-150.
65. Dale BA, Krisanaprakornkit S. Defensin antimicrobial peptides in the oral cavity. J Oral Pathol Med 2001;30:321-327.
66. Garcia JR, Krause A, Schulz S, Rodriguez-Jimenez FJ, Kluver E, Adermann K, et al. Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J 2001;15:1819-1821.
67. Harder J, Bartels J, Christophers E, Schröder JM. Isolation and characterization of human β-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001;276:5707-5713.
68. Duits LA, Ravensbergen B, Rademaker M, Hiemstra PS, Nibbering PH. Expression of β-defensin 1 and 2 mRNA by human monocytes, macrophages and dendritic cells. Immunology 2002;106:517-525.
69. Dunsche A, Acil Y, Dommisch H, Siebert R, Schröder JM, Jepsen S. The novel human beta-defensin-3 is widely expressed in oral tissues. Eur J Oral Sci 2002;109:121-124.
70. Bensch KW, Raida M, Magert HJ, Schulz-Knappe P, Forssmann WG. hBD-1: a novel beta-defensin from human plasma. FEBS Lett 1995;368:331-335.
71. O'Neil DA, Porter EM, Elewaut E, Anderson GM, Eckmann L, Ganz T, et al. Expression and regulation of the human β-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 1999;163:6718-6724.
72. Liu AY, Destoumieux D, Wong AV, Park CH, Valore EV, Liu L, et al. Human β-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. J Invest Dermatol 2002;118:275-281.
73. Dinulos JGH, Mentele L, Fredericks LP, Dale BA, Darmstadt GL. Keratinocytes expression of human β-defensin 2 following bacterial infection: role in cutaneous host defense. Clin Diagn Lab Immunol 2003;10:161-166.
74. Midorikawa K, Ouhara K, Komatsuzawa H, Kawai T, Yamada S, Fujiwara T, et al. Staphylococcus aureus susceptibility to innate antimicrobial peptides, β-defensins and CAP18, expressed by human keratinocytes. Infect Immun 2003;71:3730-3739.
75. Sørensen OE, Thapa DR, Rosenthal A, Liu L, Roberts AA, Ganz T. Differential regulation of β-defensin expression in human skin by microbial stimuli. J Immunol 2005;174:4870-4879.
76. Liu L, Wang L, Jia HP, Zhao C, Heng HHQ, Schutte BC, et al. Structure and mapping of the human β-defensin HBD-2 gene and its expression at sites of inflammation. Gene 1998;222:237-244.
77. Singh PK, Jia HP, Wiles K, Hesselberth J, Liu L, Conway BAD, et al. Production of β-defensins by human airway epithelia. Proc Natl Acad Sci U S A 1998;95:14 961-14 966.
78. Diamond G, Kaiser V, Rhodes J, Russell JP, Bevins CL. Transcriptional regulation of β-defensin gene expression in tracheal epithelial cells. Infect Immun 2000;68:113-119.
79. Takahashi A, Wada A, Ogushi K, Maeda K, Kawahara T, Mawatari K, et al. Production of beta-defensin-2 by human colonic epithelial cells induced by Salmonella enteritidis flagella filament structural protein. FEBS Lett 2001;508:484-488.
80. Hoover DM, Rajashankar KR, Blumenthal R, Puri A, Oppenheim JJ, Chertov O, et al. The structure of human β-defensin-2 shows evidence of higher order oligomerization. J Biol Chem 2000;275:32 911-32 918.
81. Hoover DM, Chertov O, Lubkowski J. The structure of human β-defensin-1. J Biol Chem 2001;276:39 021-39 026.
82. Schibli DJ, Hunter HN, Aseyev V, Starner TD, Wiencek JM, McCray PB Jr, et al. The solution structure of the human β-defensins leads to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus. J Biol Chem 2002;277:8279-8289.
83. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002;415:389-395.
84. Frye M, Bargon J, Gropp R. Expression of human beta-defensin-1 promotes differentiation of keratinocytes. J Mol Med 2001;79:275-282.
85. Harder J, Meyer-Hoffert U, Wehkamp K, Schwichtenberg L, Schröder JM. Differential gene induction of human β-defensins (hBD-1, -2, -3, and -4) in keratinocytes is inhibited by retinoic acid. J Invest Dermatol 2004;123:522-529.
86. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, et al. β-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999;286:525-528.
87. Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I. Evaluation of the effects of peptide antibiotics human β-defensin-1 /2 and LL37 on histamine release and prostaglandin D2 production from mast cells. Eur J Immunol 2001;31:1066-1075.
88. Agerberth B, Gunne H, Odeberg J, Kogner P, Boman HG, Gudmundsson GH. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci U S A 1995;92:195-199.
89. Larrick JM, Hirata M, Balint RF, Lee J, Zhong J, Wright SC. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 1995;63:1291-1297.
90. Zaiou M, Gallo RL. Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med 2002;80:549-561.
91. Ramanathan B, Davis EG, Ross CR, Blecha F. Cathelicidins: microbicidal activity, mechanisms of action, and roles in innate immunity. Microbes Infect 2002;4:361-372.
92. Larrick JW, Lee J, Ma S, Li X, Francke U, Wright SC, et al. Structural, functional analysis and localization of the human CAP18 gene. FEBS Lett 1996;398:74-80.
93. Frohm M, Agerberth B, Ahangari G, Ståhle-Bäckdahl M, Liden S, Wigzell H, et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocyte during inflammatory disorders. J Biol Chem 1997;272:15 258-15 263.
94. Nilsson MF, Sandstedt B, Sørensen O, Weber G, Borregaard N, Stahle-Backdahl M. The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect Immun 1999;67:2561-2566.
95. Malm J, Sørensen O, Persson T, Frohm-Nilsson M, Johansson B, Bjartell A, et al. The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. Infect Immun 2000;68:4297-4302.
96. Murakami M, Ohtake T, Dorschner RA, Schittek B, Garbe C, Gallo RL. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol 2002;119:1090-1095.
97. Guthmiller JM, Vargas KG, Srikantha R, Schomberg LL, Weistroffer PL, McCray PBJ, et al. Susceptibilities of oral bacteria and yeast to mammalian cathelicidins. Antimicrob Agents Chemother 2001;45:3216-3219.
98. Ouhara K, Komatsuzawa H, Yamada S, Shiba H, Fujiwara T, Ohara M, et al. Susceptibilities of periodontopathogenic and cariogenic bacteria to antimicrobial peptides, β-defensins and LL37, produced by human epithelial cells. J Antimicrob Chemother 2005;55:888-896.
99. Hirata M, Shimomura Y, Yoshida M, Morgan JG, Palings I, Wilson D, et al. Characterization of a rabbit cationic protein (CAP18) with lipopolysaccharide-inhibitory activity. Infect Immun 1994;62:1421-1426.
100. Nagaoka I, Hirota S, Niyonsaba F, Hirata M, Adachi Y, Tamura H, et al. Augmentation of the lipopolysaccharide-neutralizing activities of human cathelicidin CAP18/LL-37-derived antimicrobial peptides by replacement with hydrophobic and cationic amino acid residues. Clin Diagn Lab Immunol 2002;9:972-982.
101. Yang D, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, et al. LL37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 2000;192:1069-1074.
102. Yang D, Chertov O, Oppenheim JJ. Participation of mammalian defensins and cathelicidins in antimicrobial immunity: receptors and activities of human defensins and cathelicidin (LL-37). J Leuk Biol 2001;69:691-697.
103. Sahl HG, Pag U, Bonness S, Wagner S, Antcheva N, Tossi A. Mammalian defensins: structures and mechanism of antibiotic activity. J Leukoc Biol 2005;77:466-475.
104. Rumio C, Besusso D, Palazzo M, Selleri S, Sfondrini L, Dubini F, et al. Degranulation of Paneth cells via toll-like receptor 9. Am J Pathol 2004;165:373-381.
105. Chalifour A, Jeannin P, Gauchat JF, Blaecke A, Malissard M, N'Guyen T, et al. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood 2004;104:1778-1783.
106. Wang X, Zhang Z, Louboutin JP, Moser C, Weiner DJ, Wilson JM. Airway epithelia regulate expression of human β-defensin 2 through toll-like receptor 2. FASEB J 2003;17:1727-1729.
107. Krisanaprakornkit S, Kimball JR, Weinberg A, Darveau RP, Bainbridge BW, Dale BA. Inducible expression of human β-defensin 2 by Fusobacterium nucleatum in oral epithelial cells: multiple signaling pathways and role of commensal bacteria in innate immunity and the epithelial barrier. Infect Immun 2000;68:2907-2915.
108. Krisanaprakornkit S, Kimball JR, Dale BA. Regulation of human β-defensin-2 in gingival epithelial cells: the involvement of mitogen-activated protein kinase pathways, but not the NF-κB transcription factor family. J Immunol 2002;168:316-324.
109. Sayama K, Komatsuzawa H, Yamasaki K, Shirakata Y, Hanakawa Y, Ouhara K, et al. New mechanisms of skin innate immunity: ASK1-mediated keratinocyte differentiation regulates the expression of beta-defensins, LL37, and TLR2. Eur J Immunol 2005;35:1886-1895.
110. Hallman M, Ramet M, Ezekowitz RA. Toll-like receptors as sensors of pathogens. Pediatr Res 2001;50:315-321.
111. Takeuchi O, Akira S. Toll-like receptors; their physiological role and signal transduction system. Int Immunopharmacol 2001;1:625-635.
112. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005;17:1-14.
113. Becker MN, Diamond G, Verghese MW, Randell SH. CD14-dependent lipopolysaccharide-induced β-defensin-2 expression in human tracheobronchial epithelium. J Biol Chem 2000;275:29 731-29 736.
114. Hertz CJ, Wu Q, Porter EM, Zhang YJ, Weismuller KH, Godowski PJ, et al. Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human β defensin-2. J Immunol 2003;171:6820-6826.
115. Chamaillard M, Inohara N, Nunez G. Battling enteroinvasive bacteria: Nod1 comes to the rescue. Trends Microbiol 2004;12:529-532.
116. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307:731-734.
117. Sørensen OE, Cowland JB, Theilgaard-Monch K, Liu L, Ganz T, Borregaard N. Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J Immunol 2003;170:5583-5589.
118. Cole AM, Tahk S, Oren A, Yoshioka D, Kim YH, Park A, et al. Determinants of Staphylococcus aureus nasal carriage. Clin Diagn Lab Immunol 2001;8:1064-1069.
119. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. Activities of LL37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 1998;42:2206-2214.
120. Yeaman MR, Bayer AS, Koo SP, Foss W, Sullam PM. Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action. J Clin Invest 1998;101:178-187.
121. Xiong YQ, Yeaman MR, Bayer AS. In vitro antibacterial activities of platelet microbicidal protein and neutrophil defensin against Staphylococcus aureus are influenced by antibiotics differing in mechanism of action. Antimicrob Agents Chemother 1999;43:1111-1118.
122. Nagaoka I, Kuwahara-Arai K, Tamura H, Hiramatsu K, Hirata M. Augmentation of the bactericidal activities of human cathelicidin CAP18/LL37-derived antimicrobial peptides by amino acid substitutions. Inflamm Res 2005;54:66-73.
123. Ericksen B, Wu Z, Lu W, Lehrer RI. Antibacterial activity and specificity of the six human alpha defensins. Antimicrob Agents Chemother 2005;49:131-136.
124. Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, Nicholson G, et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor mprF is based on modification of membrane lipids with L-lysine. J Exp Med 2001;193:1067-1076.
125. Jia HP, Starner TD, Ackermann M, Kirby P, Tack BF, McCray PBJ. Abundant human beta-defensin-1 expression in milk and mammary gland epithelium. J Pediatr 2001;138:109-112.
126. Peschel A, Otto M, Jack RW, Kaibacher H, Jung G, Gotz F. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem 1999;274:8405-8410.
127. Komatsuzawa H, Ohta K, Fujiwara T, Choi GH, Labischinski H, Sugai M. Cloning and sequencing of the gene, fmtC, which affects oxacillin resistance in methicillin-resistant Staphylococcus aureus. FEMS Microbiol Lett 2001;203:49-54.
128. Jin T, Bokarewa M, Foster T, Mitchell J, Higgins J, Tarkowski A. Staphylococcus aureus resists defensins by production of staphylokinase, a novel bacterial evasion mechanism. J Immunol 2004;172:1169-1176.